HONG KONG – 3Sbio Inc. inked a proposed asset purchase agreement worth $290 million for the contract development and manufacturing organization (CDMO) business of Canada's Therapure Biopharma Inc., a deal that would mark 3Sbio's first foray into the North American biopharmaceutical sector.